1st Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$2,810,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to drug patents and exclusivities, no specific bill Patent eligibility reform, no specific bill FTC related issues, no specific bill Issues related to World Trade Organization IP waiver, no specific bill

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
JESSE KERNS —
JORDAN LYNN LAYSON —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP)

Health Issues HCR

Biosimilars reimbursement issues, no specific bill H.R. 3, Prescription drug pricing issues FDA issues, no specific bill Vial size issues Supply Chain Issues, no specific bill

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (117th)

Medicare/Medicaid MMM

S. 99 The Medicare Drug Price Negotiation Act Vial size issues, no specific bill H.R.1319- the American Rescue Plan Act of 2021 Changes to Six Protected Classes & Part D Payment Modernization model for CY22 Issues related to Drug Pricing Issues related to clinical trial diversity Issues related to osteoporosis, no specific bill Issues related to international reference pricing and Most Favored Nation (MFN) model Interim Final Rule Issues related to the 340B program, no specific bill Reimbursement for biologics/biosimilars Issues related to Part D redesign Medicare Part D access issues for plan year 2020 and 2021, no specific bill Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters Medicare End Stage Renal Disease Prospective Payment System (ESRD PPS) Proposed Rule (bundled payment for calcimimetics) Patent thickets/product hopping, no specific bill Mergers/acquisitions, no specific bill

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 99 (117th), H.R. 1319 (117th)

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico H.R. 7527, Medical Manufacturing, Economic Development, and Sustainability Act of 2020 Proposed Rule, Guidance Related to the Foreign Tax Credit, Clarification of Foreign-Derived Intangible Income H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020 Issues related to OECD negotiations on the taxation of global income

LobbyistCovered position, as disclosed
L NICOLE CURRIE —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 7527 (117th), H.R. 6930 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.